A5003739980- Hair Growth and Disorders
- Autoimmune Bullous Skin Diseases
- Dermatology and Skin Diseases
- Dermatologic Treatments and Research
- Cutaneous lymphoproliferative disorders research
- Autoimmune and Inflammatory Disorders
- Wound Healing and Treatments
- RNA regulation and disease
- Asthma and respiratory diseases
- Allergic Rhinitis and Sensitization
- Genetic and rare skin diseases.
- Fungal Infections and Studies
- Cancer and Skin Lesions
- Cytomegalovirus and herpesvirus research
- Cell Adhesion Molecules Research
- Psoriasis: Treatment and Pathogenesis
- Venous Thromboembolism Diagnosis and Management
- Skin and Cellular Biology Research
- Food Allergy and Anaphylaxis Research
- Skin Diseases and Diabetes
- Dupuytren's Contracture and Treatments
- Nonmelanoma Skin Cancer Studies
- IL-33, ST2, and ILC Pathways
- Plant Pathogens and Fungal Diseases
- Nail Diseases and Treatments
Sinclair Dermatology
2014-2025
Woolmark (Australia)
2025
Groote Schuur Hospital
2006
University College London
2003-2004
The Royal Free Hospital
2003-2004
Abstract Alopecia areata ( AA ) severity varies from a single small patch to complete loss of scalp hair, body eyelashes and eyebrows. While 40% all affected individuals only ever get one will achieve spontaneous durable remission within 6 months, 27% develop additional patches but still 12 months 33% chronic . Without systemic treatment, 55% with have persistent multifocal relapsing remitting disease, 30% ultimately alopecia totalis 15% universalis. The unpredictable course psychological...
BackgroundCharacterization of upadacitinib use and switching from dupilumab to among patients with moderate-to-severe atopic dermatitis (AD) is needed.ObjectiveTo evaluate the long-term safety efficacy continuous 30 mg after 24 weeks dupilumab.MethodsAdults who completed phase 3b clinical trial oral vs injectable 300 (Heads Up) entered a 52-week open-label extension (OLE) (NCT04195698) were included. All received 30-mg during period. We report results prespecified interim OLE 16-week...
Current measures of alopecia areata (AA) severity, such as the Severity Alopecia Tool score, do not adequately capture overall disease impact.
Abstract Background Alopecia areata (AA) is an autoimmune hair loss condition that affects people of all ages. Early age onset and prolonged disease duration indicate poor prognosis. Janus kinase inhibitors are being investigated in phase 3 clinical trials adolescents adults with AA Objective To evaluate the use oral tofacitinib pre‐adolescent patients AA. Methods A retrospective review case records treated a single center between 2018 2019. Results Fourteen were identified, aged 7 to 11...
Journal Article Corrected proof Treatment of moderate-to-severe alopecia areata with baricitinib in preadolescent children Get access Leila Asfour, Asfour Sinclair Dermatology Correspondence: Asfour. Email: leila.asfour@srft.nhs.uk https://orcid.org/0000-0002-0049-8377 Search for other works by this author on: Oxford Academic Google Scholar Laita Bokhari, Bokhari Bevin Bhoyrul, Bhoyrul Samantha Eisman, Eisman Anthony Moussa, Moussa Huw Rees, Rees https://orcid.org/0000-0003-2609-4474 Rodney...
Alopecia areata (AA) is a common immune-mediated non-scarring hair loss, with worldwide incidence between 0.57% and 3.8%. The prevalence of AA in the Australian general population have not been previously reported.To describe Australia using primary care data. A secondary objective was to identify demographic characteristics, comorbidities treatment patterns among Australians living AA.We analysed electronic health record data captured from national clinical practice management software over...
Alopecia areata (AA) is an immune-mediated disease that causes non-scarring hair loss. While acute, solitary patches often spontaneously remit, developing secondary or failure of the to resolve within 6-12 months predicts a poor prognosis, with increased risk alopecia totalis universalis. Chronic AA increases depression and suicidality reduces quality life. Treatment options for chronic acute diffuse were previously limited corticosteroids traditional immunomodulators. Two Janus Kinase (JAK)...
A recent expert consensus exercise emphasized the importance of developing a global network patient registries for alopecia areata to redress paucity comparable, real-world data regarding effectiveness and safety existing emerging therapies areata.To generate core domains domain items registries.Sixty-six participants, representing physicians, organizations, scientists, pharmaceutical industry, pharmacoeconomic experts, participated in 3-round eDelphi process, culminating face-to-face...
Baricitinib is a Janus kinase inhibitor that has been approved by the US Food and Drugs Administration for treatment of severe alopecia areata (AA) in adults. However, clinical trials demonstrated efficacy baricitinib AA did not include men aged > 60 years or women 70 years. We retrospectively assessed safety 14 patients ≥ 65 with moderate-to-severe AA. After mean (SD) duration 18.5 (11.9) months, 72% reduction Severity Alopecia Tool score from baseline was observed. Partial complete eyebrow...
Actinic keratoses are cutaneous lesions with epidermal dysplasia secondary to chronic sun exposure. Their natural history is persist, regress spontaneously, or evolve into squamous cell carcinomas. We present a case of multiple actinic treated the chemopreventative agent, oral capecitabine.
ABSTRACT We conducted a noninterventional, cross‐sectional online survey in Australia from April to July 2023 investigate the impact of alopecia areata (AA) on psychosocial well‐being, work productivity and quality life among caregivers adolescent patients with AA living Australia. The results revealed substantial occupational burden impairment mental emotional well‐being adolescents AA. These findings highlight importance recognising AA‐related that extends beyond individual patient. Trial...
ABSTRACT Background Alopecia areata (AA) is a common non‐scarring alopecia. Data continue to emerge on associations with autoimmune and other conditions. Janus kinase inhibitors (JAKi) are increasingly used treat AA. Objectives The aim was assess variation in laboratory testing patients AA among hair experts internationally compare subspecialized clinical practice current guidelines. Methods Thirty from 14 countries six continents contributed develop 24‐item survey collecting demographic...
Abstract Introduction To understand the experiences of adolescent and adult patients living with alopecia areata (AA) in Australia regarding symptom severity impact on psychosocial well‐being work/classroom productivity. Materials Methods A cross‐sectional online patient survey among diagnosed AA was recruited via Alopecia Areata Foundation. Patient‐reported outcomes were also assessed. Results total 337 (49 adolescents; 288 adults), a mean ± standard deviation age 14.7 1.55 38.9 13.31 years...
Journal Article Granulomatous mycosis fungoides presenting as an acquired ichthyosis Get access S. Eisman, Eisman Department of Dermatology, Royal Free Hospital, London Dr Samantha Pond Street, NW3 2 QG, UK. Tel.: 0207 830 2376. Fax: 020 78302247. E‐mail: sameisman@hotmail.com Search for other works by this author on: Oxford Academic Google Scholar E. A. O'Toole, O'Toole Centre Cutaneous Research, Barts and the School Medicine Dentistry, Jones, Jones Oncology, London, J. Whittaker LondonSkin...